Copper (II) bis(thiosemicarbazone) derivatives have been used extensively in positron emission tomography (PET) to image hypoxia and blood flow and to radiolabel cells for cell tracking. These applications depend on control of redox potentials and lipophilicity of the bis(thiosemicarbazone) complexes, which can be adjusted by altering peripheral ligand substituents. This paper reports the synthesis of a library of new dissymmetrically substituted bis(thiosemicarbazone) ligands by controlling the condensation reactions between dicarbonyl compounds and 4-substituted-3-thiosemicarbazides or using acetal protection. Copper complexes of the new ligands have been prepared by reaction with copper acetate or via transmetallation of the corresponding zinc complexes, which are convenient precursors for the rapid synthesis of radio-copper complexes. Well-defined structure-activity relationships linking ligand alkylation patterns with redox potential and lipophilicity of the complexes are reported.
Introduction
Cu or 62 Cu complexes with bis(thiosemicarbazonate) ligands can be used as tracers for PET (positron emission tomography) for imaging hypoxic tissues, 1-4 cerebral 5 and myocardial perfusion, [6] [7] [8] [9] changes in brain trafficking of copper associated with neurological disease, 10, 11 and for cell labelling. 12 For imaging hypoxia, Cu-diacetyl-bis(N4-methylthiosemicarbazonate) (Cu-ATSM, labelled with 64 Cu or 62 Cu), has been widely evaluated clinically. 13 The 12.7-h half-life of 64 Cu allows it to be used in centres distant from site of radionuclide production. 14 The mechanism of trapping within cells, whether hypoxia-selective or non-selective, relies on the complexes being neutral and membrane permeable, allowing them to freely diffuse into and out of cells. When in cells the complexes are converted by intracellular reducing agents to putative Cu(I)-BTSC intermediates that can rapidly dissociate, leading to intracellular trapping of the released copper. In normoxic cells Cu(I)-ATSM is capable of resisting Cu(I) dissociation long enough to be re-oxidised by molecular oxygen to Cu(II)-ATSM, which is free to diffuse back out of the cells. However, in hypoxic cells this reoxidation is slow, allowing dissociation and hence hypoxia-selective trapping within the cells. 1, 7, 13, [15] [16] [17] [18] [19] On a slower time-scale, native Cu-trafficking mechanisms can wash the trapped copper out of the cells, preventing prolonged copper retention despite the presence of hypoxia. 20 The biological behaviour and selectivity of copper bis(thiosemicarbazone) complexes depends on many factors including lipophilicity, planarity, molecular weight, pK a and redox potential. 21, 22 Investigations into the structure-activity relationships of copper bis(thiosemicarbazone) complexes have shown that the substituents at the diimine backbone ( Fig. 1 , Q 1 and Q 2 positions) are the primary determinants of the redox potential of the complex. [21] [22] [23] [24] Replacing hydrogen at Q 1 and Q 2 progressively lowers the Cu(I/II) redox potential by about 60 mV per alkyl group. Alkyl substitutions on the terminal amino groups (R 1 , R 2 , R 3 and R 4 ) have less effect on the Cu(I/II) redox potential, but do control lipophilicity. 22 Low redox potentials (i.e. below -0.5 V vs. Ag/AgCl reference electrode)
were found to be essential for hypoxic selectivity. 22 There is further scope for tuning of properties to obtain optimal complexes for the various applications. 25, 26 The value of subtle changes to the alkyl substitution patterns 22 in improving biological properties for specific applications is illustrated by recent reports of improved hypoxia imaging properties for cardiological applications. 3, 27 In this work, therefore, we aimed to extend the range of alkyl substitution patterns within the ligand from which to choose complexes with optimised properties tailored to different uses, by introducing dissymmetric ligands with two different thiosemicarbazone arms. Bis(thiosemicarbazone) pro-ligands are described here as symmetric when the substituents on the two terminal nitrogens are the same, and dissymmetric when the substituents on the terminal nitrogens are dissimilar (NR 1 R 2 ≠NR 3 R 4 ). Almost all ligands evaluated in PET imaging to date are symmetric in this respect. Dissymmetric ligands can be further classified as singly dissymmetric or doubly dissymmetric with respect to the backbone substituents Q 1 and Q 2 . When the substituents on the backbone are identical (Q 1 =Q 2 ) they can be classed as singly dissymmetric and if they are dissimilar (Q 1 ≠Q 2 ) they are doubly dissymmetric.
Symmetric pro-ligands 7, 22, 26, [28] [29] [30] [31] [32] [33] [34] are typically synthesised by addition of at least two equivalents of a 4-substituted-thiosemicarbazide to a vicinal diketone under acid catalysis. The synthesis of dissymmetric bis(thiosemicarbazone) pro-ligands, first reported by Green and co-workers, 35 has been reviewed. 36 The most generally applicable approach involves protection of one of the carbonyl groups, for example reacting isonitroacetone with a chosen thiosemicarbazide (Fig. 2 ) giving an intermediate which is then deprotected and reacted with a second (dissimilar) thiosemicarbazide. Lim et al. reported 35 that this method gave a mixture of symmetric and dissymmetric bis(thiosemicarbazones). Similarly, use of acetal protection to control reaction with the first thiosemicarbazide, 35, 37, 38 followed by hydrolysis of the acetal before treating with the second, has been reported for Q 1 = CH 3 and Q 2 = H (Fig. 2) . Hydrolysis of the imine group during the deprotection step can be avoided by using the mild Lewis acid lithium tetrafluoroborate (LiBF 4 ) as the catalyst (Fig.  2) . 35 Stepwise addition of two thiosemicarbazides to an unprotected diketone ( Fig. 2) has also been used. The mono(thiosemicarbazone) formed initially precipitates and can be isolated and reacted with a second thiosemicarbazide under more forcing conditions. 39, 40 This method has been used to make dissymmetric bis(thiosemicarbazone) pro-ligands with Q 1 = Q 2 = Me, 30, [39] [40] [41] [42] [43] [44] and Q 1 = Me, Q 2 = H 36,39 but yields mixed bis(thiosemicarbazone) proligands and cyclic by-products in some cases. proligands have been reported in which one side arm is modified to improve water solubility (using a carbohydrate 48 or sulfonate 39 ), introduce fluorescence 49 or radiolabel with fluorine-18. 50 These proligands were derived from a dissymmetric bis(thiosemicarbazone) in which one thiosemicarbazide arm is a thiocarbohydrazide 40, [42] [43] [44] 51 (Fig. 2 ).
The aims of the present work were to expand the available library of BTSC complexes to include more dissymmetric ones from which to choose fine-tuned properties for PET applications, evaluate transmetallation as a method to synthesise the copper complexes from the zinc (II) complexes, and measure the effects of the resulting different alkylation patterns on redox potential and lipophilicity. Fig. 2 . Literature routes to synthesis of dissymmetric bis(thiosemicarbazone) pro-ligands using isonitrone or acetal protection and using unprotected diketones, and dissymmetric functionalisation via a thiocarbohydrazide side arm.
Results and Discussion
BTSC ligands with two different thiosemicarbazone arms were synthesised via a range of strategies as described below, with less than 5% contamination by scrambled or symmetric proligands unless otherwise noted. Mono(thiosemicarbazone) intermediates, listed in Table 1 , are referred to by a letter designation A -M, while bis(thiosemicarbazone) pro-ligands (Table 2) are referred to by a numeric designation 1 -36. When used to define their Cu(II) and Zn(II) complexes, the numeric designation implies coordination in the form of the doubly-deprotonated dianion. BTSC ligands with two identical thiosemicarbazone arms (1, 2, 5, 6, 7, 8, 20, 21, 25) were prepared following a previously reported procedure 22 and obtained in high yield and purity.
Synthesis of Pro-ligands via Protected Dicarbonyls
Using the method of Green 35 ( Fig. 3 ), 4-methyl-3-thiosemicarbazide was reacted with methylglyoxal-1,1-dimethylacetal in DMF to give A, which was deprotected to give B (and D was prepared analogously from C). However, B was more conveniently prepared directly by aqueous reaction of 4-methyl-3-thiosemicarbazide with methylglyoxal-1,1-dimethylacetal; H and I were directly prepared analogously from methylglyoxal-1,1-dimethylacetal. B was reacted with thiosemicarbazide to afford the known dissymmetric pro-ligand 3 35 in 6% overall yield. Again in a similar manner to Green, reversing the order of thiosemicarbazide addition gave intermediates C and D and pro-ligand 4 35 in 4% overall yield. Applying this strategy to 3,3-dimethoxy-2-butanone to prepare E required use of ethanol as the reaction solvent followed by extraction with diethyl ether. Intermediate E is a precursor to F, which has been more conveniently prepared by Holland et al. using the diketone route (Fig. 2 ). 
Synthesis of Pro-ligands via Unprotected Diketones
Dissymmetric pro-ligands can be prepared from 2,3-butanedione via mono-substituted-3-thiosemicarbazone intermediates (Fig. 2) . Reaction of 2,3-butanedione with one equivalent of thiosemicarbazide, 4-methyl-3-thiosemicarbazide or 4,4-dimethyl-3-thiosemicarbazide affords G, F 40 and J, respectively. Reaction of F with thiosemicarbazide, and G with 4,4-dimethyl-3-thiosemicarbazide, affords the new pro-ligands 23 and 24 respectively in good yield and purity. 23 could also be prepared by addition of the thiosemicarbazide arms in the reverse order, i.e. reaction of F with thiosemicarbazide; similarly, 22 was prepared by reaction of F with 4,4-dimethyl-3-thiosemicarbazide.
Doubly dissymmetric pro-ligands could be synthesised by exploiting the reactivity difference between the ethyl and methyl ketone functionalities of 2,3-pentanedione: reaction with thiosemicarbazide affords K (in which the reaction has occurred at the methyl ketone) in 66% yield with a 9% impurity in which the thiosemicarbazide reacted with the ethyl ketone. Similarly, reactions with 4-methyl-3-thiosemicarbazide and 4-ethyl-3-thiosemicarbazide afford L and M with 4% and 10% impurities respectively. Given this high degree of selectivity, the ethyl ketone intermediates were reacted with further thiosemicarbazides to afford new doubly asymmetric pro-ligands 26, 27, 28, 29 and 30, with less than 5% of the minor isomers with the position of the arms reversed (see supplementary information).
Synthesis of Complexes
Known Cu-BTSC complexes were synthesised and purified following a previously reported protocol. 22 
Electrochemistry
Cyclic voltammetry was performed on all complexes whose HPLC indicated sufficient purity (i.e. <5% contamination with possible scrambled or isomeric complexes) using a glassy carbon working electrode with ferrocene as an internal standard. ). All complexes measured showed a quasi-reversible one-electron reduction (e.g., Fig. 3 ). In addition, quasireversible Cu(II/III) processes were observed whose potentials could be similarly determined in some cases. Measurement of the Cu(I/II) electrode potentials of Cu(1), Cu (20) and Cu(25), whose electrochemistry has been reported previously, 22, 56, 57, 58 enabled combination and comparison of the new data with previously published data, by correcting the difference in reference electrode (subtracting 530 mV from values in ref. 22 ). These previously published data are also included, after adjustment in this way, in Table 2 (denoted with asterisk). The structure-activity relationships were in accord with previous observations 22, 56, 57, 58 (Fig. 4) , showing that the dissymmetric complex Cu (I/II) redox potentials, like those of the previously reported symmetric ones, correlated with the number of alkyl groups at Q 1 and Q 2 (with Cu(I/II) redox potentials lowered by 73 mV per alkyl group, as determined from the regression line in Fig. 4 ) while the terminal alkylation pattern (R 1 , R 2 , R 3 , R 4 ) lowered this redox potential much less (17 mV per alkyl group when there were alkyl groups at both Q 1 and Q 2 ); those compounds with two alkyl groups at the Q 1 and Q 2 positions showed low and tightly-grouped Cu(I/II) redox potentials (Fig. 4) . In contrast, the spread of Cu(II/III) redox potentials was much less and there was no clear correlation with alkylation at Q 1 and Q 2 or R 1 -R 4 . 
LogP measurement
Reversed-phase HPLC was used to estimate the lipophilicity of the newly synthesised Cu-BTSC complexes as an alternative to octanol-water partitioning. Lipophilicity assessment by reversedphase HPLC assumes a linear relationship between the logarithm of the retention factor of the compound (logK) 59 Figure 5 ), which was indeed linear and was used to calculate the logP values of the new Cu-BTSC complexes, which are summarised in Table 2 (with those used for the calibration marked with an asterisk). As expected, higher logP values correlated with greater molecular weight, with complexes having phenyl groups in their structure being the most lipophilic. Although the effect of alkylation on logP is expected to vary with location and identity of the alkyl/aryl group, it is clear that alkylation of both the diimine backbone and pendant amino arms contributed to enhancing the lipophilicity of Cu-BTSCs (by 0.16 per alkyl group on average, from linear least squares regression of logP and total number of alkyl groups at R 1 -R 4 and Q 1 -Q 2 ; see supplementary information). Recent mechanistic studies with hypoxia-targeting copper(II) bis(thiosemicarbazone) complexes, combined with in vivo studies in rodent tumour models, suggest that the combination of redox potential and lipophilicity offered by CuATSM (Cu(20)) may not be ideal for hypoxia imaging and that less lipophilic complexes may give improved pharmacokinetics. In particular, CuATS (Cu(33))and CuCTS (Cu(25)) showed improved clearance from non-hypoxic tissue and superior hypoxic-tonormoxic tissue uptake ratio, as well as a more favourable pO 2 threshold of selectivity, warranting in vivo evaluation for cardiac hypoxia imaging, based on experiments in the Langendorff isolated perfused rat heart model. 3, 27 Both have a similar redox potential but reduced lipophilicity compared to CuATSM. By including complexes with dissymmetric ligands, which are now accessible by the methods described here, the library of compounds for biological evaluation with lipophilicity and redox potential similar to CuATS and CuCTS can be extended to allow selection of optimal complexes for hypoxia imaging in different clinical contexts. In particular, Cu(23), Cu(24), Cu(26) and Cu(29), among these compounds, should be evaluated biologically as they have logP values comparable to those of CuATS and CuCTS and slightly lower than that of CuATSM, and Cu(I/II) redox potentials in the appropriate range.
Conclusions
This paper reports the synthesis of new dissymmetrically substituted bis(thiosemicarbazone) ligands in high purity by controlling the condensation reactions between dicarbonyl compounds and 4- UV-1800 spectrometer. A Bruker micrOTOF-Q mass spectrometer was used to record positive mode ESI mass spectra. Samples were dissolved in DMSO at a concentration of 1 mg/ml before being diluted 1 in 100 in methanol. 10 µL of sample solution was injected into a flowing stream of 10 mM ammonium acetate in 95% methanol in water (flow rate: 0.02 mL/min) and the flow directed into the electrospray source of the spectrometer. Data were processed in Bruker's Compass Data Analysis software utilising a lock mass.
Cyclic voltammograms were recorded using a μAUTOLAB potentiostat (Metrohm Autolab B. V., Netherlands) and General Purpose Electrochemical System (GPES) acquisition and analysis software, with a scan rate of 0.1 V/s under argon using a glassy carbon working electrode, a silver wire pseudo-reference electrode and a platinum auxiliary electrode, in DMSO (5 mL) with tetrabutylammonium hexafluorophosphate (0.1 M, Sigma Aldrich) as a support electrolyte and a Cucomplex concentration of 0.5 mM. All potentials were referenced to the internal standard ferrocene/ferrocenium couple. The redox potentials were calculated as the midpoint between the reduction and oxidation peaks.
Reversed phase HPLC was used both to determine purity and lipophilicity (logP) of new copper complexes, using an Eclipse XDB-C 18 column (4. 
Synthesis of C:
Freshly activated molecular sieves (3 Å, 0.801 g) was added to DMF (15 mL, 60 o C),
followed by the addition of thiosemicarbazide (0.770 g, 0.0084 mol). This was followed by the addition of methylglyoxal-1,1-dimethylacetal (1 mL, 0.0083 mol, 1 g). The resulting solution was left to stir (room temperature, 3 days). The molecular sieves were filtered off and the DMF was removed under vacuum. The crude product was washed with a little diethyl ether and dried. An off white solid (0.769 g) was recovered (48% yield The precipitate was recovered via filtration, washed with de-ionised water (2 x 30 mL). The crude was recrystallized from ethanol in a freezer. The crystalline solid was filtered off, washed with petroleum ether (2 x 10 mL) and left to dry. A bright yellow crystalline solid (0.191 g) was recovered (25% yield 22 were synthesised as described previously.
Proligands 1 -30
Previously reported proligands 6, 7, and 8 were synthesised by new methods described below. Other previously reported proligands listed in Table 2 were not synthesised in this work and their data reported in Table 2 are literature values.
Synthesis of 3:
Compound B (0.510 g, 0.0032 mol) was dissolved in DMF (3 mL) and filtered. Thiosemicarbazide (0.292 g, 0.0032 mol) was dissolved in DMF (10 mL), HCl (10%, 2 drops) was added and filtered. The two solutions were combined and left to stir (room temperature, 5 hours).
De-ionised water (26 mL) was added, the precipitate was filtered off and washed with de-ionised water (50 mL, room temperature and 50 mL, 80 o C). The crude product was dissolved in DMSO (10 mL) the resulting solution was filtered and recrystallised with de-ionised water (20 mL 
Synthesis of 7:
4-ethyl-3-thiosemicarbazide (1.251 g, 0.0105 mol) was dissolved in de-ionised water (50 mL, 50 o C). The insoluble particulates were filtered and HCl was added (32%, 2 drops).
Methylglyoxal-1,1-dimethylacetal (0.58 mL, 0.0048 mol, 0.57 g) was added rapidly and left to stir (50 o C, 5 minutes). The precipitate was removed by filtration and washed with de-ionised water (50 mL).
The crude product was dissolved in DMSO (35 mL). The solution was filtered and the product was recrystallised with de-ionised water (70 mL). The precipitate was isolated via filtration, washed with water (50 mL) and dried. A yellowish white solid (0.870 g) was recovered (66% yield 
Synthesis of 9:
Compound B (0.255 g, 0.0016 mol) was dissolved in DMF (1.5 mL) and filtered. 4,4-dimethyl-3-thiosemicarbazide (0.191 g, 0.0016 mol) was dissolved in DMF (3 mL), HCl (10%, 1 drop) was added and filtered. The two solutions were combined and left to stir (room temperature, 5 hours). De-ionised water (9 mL) was added, the precipitate was filtered off and washed with deionised water (50 mL, room temperature and 50 mL, 80 o C). The crude product was dissolved in DMSO (9 mL), filtered and recrystallised with de-ionised water (18 mL 
Synthesis of 11:
Compound H (0.554 g, 0.0032 mol) was dissolved in DMF (2 mL) and filtered. 4-methyl-3-thiosemicarbazide (0.337 g, 0.0032 mol) was dissolved in DMF (6 mL), HCl (10%, 2 drops) was added and filtered. The two solutions were combined and left to stir (room temperature, 5 hours). De-ionised water (50 mL) was added, a gelatinous precipitate was recovered by filtration and washed with de-ionised water (50 mL, room temperature and 50 mL, 80 o C). The crude product was left on the water pump until its volume decreased then dissolved in DMSO (6 mL), filtered and recrystallised with de-ionised water (60 mL 
Synthesis of 12:
Intermediate B (0.255 g, 1.6 mmol) was dissolved in DMF (2 mL) and filtered. 4-phenyl-3-thiosemicarbazide (0.268 g, 1.6 mol) was dissolved in DMF (2.5 mL), HCl (10%, 1 drop) was added and filtered. The two solutions were combined and left to stir for 5 h. De-ionised water (9 mL) was added, the precipitate was filtered and washed with de-ionised water (50 mL, room temperature and 50 mL, 80 o C). The crude product was dissolved in DMSO (12 mL), filtered and recrystallised with de-ionised water (24 mL 
Synthesis of 13:
Compound H (0.554 g, 0.0032 mol) was dissolved in DMF (2 mL) and filtered. Thiosemicarbazide (0.292 g, 0.0032 mol) was dissolved in DMF (10 mL), HCl (10%, 2 drops) was added and filtered. The two solutions were combined and left to stir (room temperature, 5 hours).
De-ionised water (24 mL) was added, the precipitate was filtered off and washed with de-ionised water (50 mL, room temperature and 50 mL, 80 o C). The crude product was dissolved in DMSO (25 mL), filtered and recrystallised with de-ionised water (50 mL 
Synthesis of 14:
Compound H (0.277 g, 0.0016 mol) was dissolved in DMF (1.5 mL) and filtered. 4,4-dimethyl-3-thiosemicarbazide (0.191 g, 0.0016 mol) was dissolved in DMF (3 mL), HCl (10%, 1 drop) was added and filtered. The two solutions were combined and left to stir (room temperature, 5 hours). De-ionised water (24 mL) was added, the precipitate was filtered and washed with deionised water (2 x 50 mL). The crude product was dissolved in DMSO (7 mL), filtered and recrystallised with de-ionised water (14 mL 
Synthesis of 17:
Compound I (0.354 g, 0.0016 mol) was dissolved in DMF (2.5 mL) and filtered. 4-methyl-3-thiosemicarbazide (0.168 g, 0.0016 mol) was dissolved in DMF (4 mL), HCl (10%, 1 drop) was added and filtered. The two solutions were combined and left to stir (room temperature, 5 hours). De-ionised water (13 mL) was added, the precipitate was filtered and washed with deionised water (50 mL, room temperature and 50 mL, 
Synthesis of 19:
Compound I (0.354 g, 0.0016 mol) was dissolved in DMF (2.5 mL) and filtered. 4-ethyl-3-thiosemicarbazide (0.191 g, 0.0016 mol) was dissolved in DMF (5 mL), HCl (10%, 1 drop) was added and filtered. The two solutions were combined and left to stir (room temperature, 5 hours).
De-ionised water (15 mL) was added, the precipitate was filtered and washed with de-ionised water (50 mL, room temperature and 50 mL, 80 o C). The crude product was dissolved in DMSO (11 mL), filtered and recrystallised with de-ionised water (22 mL). The precipitate was recovered by filtration, washed with de-ionised water (50 mL, room temperature and 50 mL, dissolved in 100 mL of cold distilled water (0 °C) in a conical flask. Five drops of concentrated HCl (97%) were added to the reaction mixture, followed by 4-methyl-3-thiosemicarbazide (3.45 g, 32.8 mmol). After stirring for 1 hour, the resulting suspension was filtered and the residue rinsed with water (3 x 100 mL), ethanol (3 x 50 mL) and diethyl ether (3 x 10 mL) and recrystallised from warm ethanol to afford pure mono-substituted-3-thiosemicarbazone intermediate (2.4 g, 43%) . This intermediate (0.80 g, 4.62 mmols) was added over 2 h in portions to a solution of thiosemicarbazide in methanol (0.44 g, 4.82 mmol) previously acidified with concentrated HCl. The reaction mixture was heated under reflux (~65 °C) for 5 h, during which a whitish suspension formed. After cooling down to room temperature, the solution was filtered under vacuum and the precipitate washed with ethanol (3 x 50 mL) and diethyl ether (3 x 10 mL). The resulting solid was then recrystallised from warm DMSO/water (50:50) to yield pure 23 (0.90 g, 79%).
Synthesis of 24:
Intermediate G (0.255 g, 1.6 mmol) was dissolved in DMF (1.5 mL) and filtered. 4,4-dimethyl-3-thiosemicarbazide (0.191 g, 1.6 mmol) dissolved in DMF (2.5 mL), HCl (10%, 2 drops) was added and filtered. The two solutions were combined and left to stir for 5 h. De-ionised water (33 mL) was added, the precipitate was recovered by filtration and washed with de-ionised water (50 mL, room temperature and 50 mL, 80 o C). The crude product was dissolved in DMSO (3 mL), filtered and recrystallised with de-ionised water (6 mL). The precipitate was filtered off, washed with deionised water (50 mL, room temperature and 50 mL, 
Synthesis of 26:
Intermediate K (0.277 g, 1.6 mmol) was dissolved in DMF (3 mL). 4-methyl-3-thiosemicarbazide (0.168 g, 1.6 mmol) was dissolved in DMF (4 mL) and HCl (10%, 1 drop) was added. The two solutions were combined and left to stir for 5 h. De-ionised water (14 mL) was added, the precipitate was filtered and washed with de-ionised water (50 mL). The crude product was dissolved in DMSO (8 mL) and recrystallised with de-ionised water (16 mL). The precipitate was filtered off, washed with de-ionised water (50 mL), ethanol (5 x 10 mL) and dried. A yellow/white solid (0.275 g) was recovered (66% yield). δ 
Synthesis of 27:
Intermediate K (0.452 g, 2.6 mol) was dissolved in DMF (2 mL) and filtered. 4,4-dimethyl-3-thiosemicarbazide (0.310 g, 2.6 mmol) was dissolved in DMF (4 mL), HCl (10%, 2 drops) was added and filtered. The two solutions were combined and left to stir for 5 h. De-ionised water (37 mL) was added and solution was put in the freezer (10 min). The precipitate was filtered off and washed with de-ionised water (50 mL, room temperature and 50 mL, 80 o C). The crude product was dissolved in DMSO (3.5 mL), filtered and recrystallised with de-ionised water (60 mL). The precipitate was recovered by filtration, washed with de-ionised water (2 x 50 mL) and dried. A yellow solid (0.171 g) was recovered (24% yield 
Synthesis of 28:
Intermediate K (0.277 g, 1.6 mmol) was dissolved in DMF (3 mL). 4-ethyl-3-thiosemicarbazide (0.191 g, 1.6 mmol) was dissolved in DMF (5 mL) and added HCl (10%, 1 drop) was added. The two solutions were combined and left to stir for 5 h. De-ionised water (14 mL) was added, the precipitate was filtered off and washed with de-ionised water (50 mL). The crude product was dissolved in DMSO (8 mL), filtered and recrystallised with de-ionised water (16 mL 
Synthesis of 29:
Intermediate L (0.599 g, 3.2 mmol) was dissolved in DMF (2 mL) and filtered. Thiosemicarbazide (0.292 g, 3.2 mmol) was dissolved in DMF (10 mL), HCl (10%, 2 drops) was added and filtered. The two solutions were combined and left to stir for 5 h. De-ionised water (24 mL) was added, the precipitate was filtered off and washed with de-ionised water (50 mL, room temperature and 50 mL, 80 o C). The crude product was dissolved in DMSO (31 mL), filtered and recrystallised with de-ionised water (62 mL). The precipitate was recovered by filtration, washed with de-ionised water (50 mL, room temperature and 50 mL, 80 o C) and dried. An off white solid (0.597 g) was recovered (72% yield (36) were not synthesised in this work; any data reported in Table 2 are derived from literature values. Other copper complexes were synthesised by a generic method as follows: Bis(thiosemicarbazone) pro-ligands (0.6 mmol) were added to a NaOH solution (1M, 13 mL, 50 o C), the minimum amount of DMF was added to achieve full dissolution. Copper (II) acetate monohydrate (0.140 g, 0.7 mmol) was dissolved in de-ionised water (5 mL). The solutions were combined and left to stir overnight. The precipitate was recovered via filtration, washed with methanol (3 x 10 mL) and de-ionised water (1 x 10 mL). The products were dried in air. 
Synthesis of Zinc Complexes
Exemplar zinc bis(thiosemicarbazonate) complexes listed below were synthesised by a generic method as follows: the bis(thiosemicarbazone) pro-ligand (0.6 mmol) was added to ethanol (15 mL). Anhydrous zinc (II) acetate (0.128 g, 0.7 mmol) was added to the suspension. The suspension was then brought to reflux for 2 h. The yellow-orange precipitate was recovered via filtration, washed with ethanol (1 x 15 mL) and diethyl ether (5 x 15 mL). The solid was dried in air. 
Data for

Transmetallation Reactions
Zn(14) (0.027g (0.08 mmol) was dissolved in DMSO (1 mL). Copper acetate monohydrate (0.018g 0.09 mmol) was dissolved in deionised water (1 mL). The solutions were combined and stirred for 5 mins. The solution changed rapidly to a brown colour. The precipitate was recovered by filtration, washed with water (10 mL) and diethyl ether (10 mL) and dried in air. A brown solid (0.026 g) was recovered (91% yield). Cu(17) and Cu(29) were prepared similarly in yields of 49% and 74% respectively. Spectroscopic properties of these three copper complexes matched those of their counterparts synthesised as described above. 
